UK– tag –
-
UK Series (Final): Case Studies: Execution from the UK in Practice (3–5 Short Cases)
Executive Summary｜This collection grounds Parts 1–4 in practice: a rare-disease PoC, a multi-ancestry stratified trial, access optimization, manufacturing × capital structuring, and a repurposing example. Each case includes a ready-to-u... -
UK Series (Part 3): From Genomes to Targets: Biomarkers, Stratification, and Repurposing at Scale
Executive Summary｜UK-scale WGS and multi-ancestry GWAS enable earlier, stronger target validation, biomarker design, indication shaping, and safety anticipation. This article turns discoveries into practice—workflows, metrics, QC, and p... -
UK Series (Part 2): Data-Driven UK: How WGS and Multi-Ancestry GWAS Rewire Drug Discovery
Executive Summary｜The UK’s edge lies in its public data infrastructure. With ~490k whole-genome sequences (WGS) extending into non-coding, rare variants, and structural variation—and a multi-ancestry GWAS program (Pan-UK Biobank)—the ec... -
UK Series (Part 1): The UK Life Sciences Strategy: Policy, Regulation, and Investment at Full Tilt
Executive Summary｜The UK’s 2025 industrial strategy update places life sciences among its priority sectors, aiming to become Europe’s No.1 by 2030 and the world’s No.3 by 2035. In lockstep with the NHS long-term roadmap, the plan combin...
1